A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results for " Trametinib "

Trametinib is a kinase inhibitor used alone or in combination with dabrafenib to treat cancers harboring specific BRAF mutations, such as melanoma and non-small cell lung cancer. It is a MEK inhibitor with demonstrated anti-cancer activity.


SynZeal is a leading innovator in pharmaceutical reference standards. We supply high-quality Reference Standards of Trametinib, pharmacopeial and non-pharmacopeial Trametinib impurities, metabolites, stable isotope products, and nitrosamines (N-NO products). Trametinib impurities reference standards are useful in pharmaceutical research. They are useful in product development, ANDA and DMF filing, quality control (QC), method validation, and stability studies. It is also useful in the identification of unknown impurities and the assessment of genotoxic potential.

Trametinib-related products are thoroughly characterized. Trametinib products are supplied with detailed COA & analytical data meeting regulatory compliance. We can also provide EP/USP traceable standards based on your requirements. The supplied products are re-tested at regular intervals.